Tryptamine Therapeutics Limited
TYPTF
$0.01
$0.00-6.67%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.12% | 68.77% | 2.75% | -7.55% | 32.97% |
| Total Depreciation and Amortization | 1.87% | 62.12% | -2.94% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.12% | 216.01% | 2.74% | -323.61% | -49.74% |
| Change in Net Operating Assets | -2.12% | -- | -- | 202.46% | -109.73% |
| Cash from Operations | -2.12% | 47.55% | 2.75% | -75.12% | 15.46% |
| Capital Expenditure | 0.00% | 93.13% | 2.72% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | -- | -- | -- | -- |
| Cash from Investing | -2.50% | 89.82% | 2.72% | -- | -- |
| Total Debt Issued | -- | -- | -- | -99.17% | 1,356.74% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | 18.18% | 0.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -4.36% | 0.00% | -- | -- |
| Cash from Financing | 2.13% | 14.79% | -2.75% | -99.25% | 1,321.83% |
| Foreign Exchange rate Adjustments | -2.42% | -190.31% | -2.74% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.08% | 107.66% | 2.75% | -198.87% | 277.17% |